{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:50:47Z","timestamp":1782219047761,"version":"3.54.5"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.neuroscience.2026.01.042","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T23:20:30Z","timestamp":1769901630000},"page":"59-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dopamine antagonists-induced parkinsonism: the crucial role of individual susceptibility associated to positive family history"],"prefix":"10.1016","volume":"598","author":[{"given":"Stefano","family":"Calzetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Negrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.01.042_b0005","first-page":"737","article-title":"Le syndrome extra-pyramidal et di-encephalique au cours des traitments au Largactil et au Serpasil","volume":"112","author":"Steck","year":"1954","journal-title":"Ann. Med-Psychol."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archneur.1962.00450190007002","article-title":"Hereditary predisposition in drug-induced parkinsonism","volume":"6","author":"Myrianthopoulos","year":"1962","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.01.042_b0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.870040203","article-title":"HLA antigens in drug-induced parkinsonism","volume":"4","author":"Metzer","year":"1989","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.01.042_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00002826-199202000-00003","article-title":"Parkinsonism associated with calcium channel blockers: a prospective follow-up study","volume":"13","author":"Garc\u00eda-Ruiz","year":"1992","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0025","first-page":"261","article-title":"Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility","volume":"13","author":"Negrotti","year":"1992","journal-title":"Neurotoxicology"},{"issue":"2","key":"10.1016\/j.neuroscience.2026.01.042_b0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00002826-199104000-00005","article-title":"Cinnarizine-induced parkinsonism. susceptibility related to aging and essential tremor","volume":"14","author":"Gim\u00e9nez-Rold\u00e1n","year":"1991","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0035","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41598-018-37901-z","article-title":"Flunarizine related movement disorders: a nationwide population based study","volume":"9","author":"Jhang","year":"2019","journal-title":"Sci. Report."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0040","first-page":"1","article-title":"Outcome of drug-induced parkinsonism in the elderly: a permanent non-progressive parkinsonian syndrome may occur following discontinuation of cinnarizine and flunarizine","author":"Calzetti","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00228-006-0234-8","article-title":"Antipsychotic-related extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms","volume":"63","author":"G\u00fczey","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euroneuro.2010.06.006","article-title":"Searching for functional SNP or rare variants in exonic regions of DRD3 in risperidone\u2013treated patients","volume":"21","author":"Gasso\u2019","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00213-010-2079-1","article-title":"Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility","volume":"214","author":"Kasten","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.01.042_b0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neulet.2009.11.043","article-title":"Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-related parkinsonism in Japanese patients with schizophrenia: results from Juntendo University Schizophrenia Projects (JUSP)","volume":"469","author":"Higa","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fneur.2015.00027","article-title":"Pharmacogenetics of antipsychotics-induced movement disorders as a resource for better understanding Parkinson\u2019s disease modifier genes","volume":"6","author":"Greenbaum","year":"2015","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0070","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fgene.2018.00701","article-title":"Elucidating conserved transcriptional networks underlying pesticide exposure and parkinson\u2019s disease: a focus on chemicals of epidemiological relevance","volume":"9","author":"Cao","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.neuroscience.2026.01.042_b0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tox.2013.01.017","article-title":"Epigenetics and pesticides","volume":"307","author":"Collotta","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.neuroscience.2026.01.042_b0080","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.2008.147223","article-title":"on behalf of the Neurological Disorders in Central Spain (NEDICES) study group, risk of incident Parkinson\u2019s disease and parkinsonism in essential tremor: a population based study","volume":"80","author":"Benito Le\u00f3n","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:06:36Z","timestamp":1782216396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"alternative-id":["S0306452226000795"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.01.042","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopamine antagonists-induced parkinsonism: the crucial role of individual susceptibility associated to positive family history","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}